Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Urogen's Phase 2 NMIBC Trial Results

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Oct 07, 2021 4:35pm

506 Views

Post# 33983907

RE:RE:Urogen's Phase 2 NMIBC Trial Results

This would be a first line treatment. It could be a replacement for the TURBT surgery that comes before BCG treatment. If successful it might reduce the number of patients that end up BCG-unresponsive. But that's a long way down the road as they don't even have approval for a phase 3 trial yet.